Loading the page…
Nasdaq 100
AMGN
Amgen Inc., Health Care
$466.01
+1.15% on the day
Close of Fri, Oct 30, 2026
+21.7% over 3M
2026-07-312026-09-162026-10-30
Market cap$251.9B
Last close$466.01
Day move+1.15%
Nasdaq 100
Amgen Inc., Health Care
$466.01
+1.15% on the day
Close of Fri, Oct 30, 2026
| Quarter ending | Jun 2026 | Mar 2026 | Dec 2025* | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024* | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.1B | $8.6B | $9.9B | $9.6B | $9.2B | $8.1B | $9.1B | $8.5B |
| Gross margin | 72.0% | 68.2% | 69.8% | 67.8% | 67.2% | 63.6% | 65.7% | 61.1% |
| Operating margin | 35.0% | 30.9% | 27.6% | 26.4% | 28.9% | 14.5% | 25.4% | 24.1% |
| Net margin | 23.6% | 21.1% | 13.5% | 33.7% | 15.6% | 21.2% | 6.9% | 33.3% |
| EPS, diluted | $4.37 | $3.34 | $2.45 | $5.93 | $2.65 | $3.20 | $1.17 | $5.22 |
From the company's SEC filings, newest first. * A fiscal fourth quarter: the year's 10-K less its first three quarters.
The same ranks the builder's sliders blend. Small and Wild are Big and Calm turned over.
| Measure | AMGN | Higher than |
|---|---|---|
| Earnings yield (earnings ÷ price) | 3.5% | 61% |
| Book yield (book value ÷ price) | 4.6% | 16% |
| Free cash flow yield | 3.2% | 60% |
| Buyback yield | 0.0% | 0% |
| Revenue growth, a year | 10.0% | 42% |
| EPS growth, a year | 88.2% | 81% |
| Return on equity | 74.8% | 92% |
| Return on assets | 9.1% | 45% |
| Net margin | 23.0% |
Research
Figures from SEC filings and daily closes; results dates and headlines from Yahoo Finance and Nasdaq; insider trades from SEC Form 4. For learning, not investment advice.
| 65% |
| Liabilities ÷ assets | 87.8% | 93% |
|---|
| Past year, skipping last month | 43.5% | 74% |
|---|
| Past 6 months, skipping last month | 25.1% | 80% |
|---|
| Volatility, a year's worth | 33.8% | 39% |
|---|
"Higher than" is the share of the 100 with a lower figure. Financial figures from SEC filings, market figures from daily closes. Dividend yield and beta are under Valuation below.
Beat the forecast in 4 of the last 4 quarters.
The stock's move is from the close before the report to the close after it.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients…
From Yahoo Finance, amgen.com
Looking For Growth, Income, and Stability? This Stock Could Offer All 3Motley Fool, 4h ago
Dow Jones Futures: Stock Market Sells Off As Apple, Palantir, Midterm Elections Loom; What To DoInvestor's Business Daily, 9h ago
Amgen (AMGN) Gets A Fresh Look As Phase 3 Wins Meet A Pricey NarrativeSimply Wall St., 15h ago
New CFO Appointment Could Be A Big Moment For Mattel (MAT)Simply Wall St., 15h ago
Big Homes, Big LoansBarrons.com, 23h agoHeadlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Looking For Growth, Income, and Stability? This Stock Could Offer All 3Motley Fool, 4h agoDow Jones Futures: Stock Market Sells Off As Apple, Palantir, Midterm Elections Loom; What To DoInvestor's Business Daily, 9h agoAmgen (AMGN) Gets A Fresh Look As Phase 3 Wins Meet A Pricey NarrativeSimply Wall St., 15h agoNew CFO Appointment Could Be A Big Moment For Mattel (MAT)Simply Wall St., 15h agoBig Homes, Big LoansBarrons.com, 23h ago
Stocks Fall Sharply on Intel and Amazon Sell-offs and Crypto HeistBarchart, Oct 30
Regeneron Soars 12% on Dupixent-Fueled Q3 Beat: “One of Our Strongest Years Ever”TIKR, Oct 30
AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling StockBarrons.com, Oct 30
AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales GrowthZacks, Oct 30
How to Build $6,800 a Month in Dividend Income Without Selling a Single Share24/7 Wall St., Oct 30Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Picked by YouTube search, not by us. Someone else's view, not advice.
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
Every transaction, in AdvancedSEC Form 4, public domain. The latest 40 of 86 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Khosla RachnaSVP, Business Development | Option exercise | +1,252 | $162.60 | $204K | Form 4 ↗ |
| Aug 13, 2026 | Khosla RachnaSVP, Business Development | Sold on the market | −1,252 | $416.43 | $521K | Form 4 ↗ |
| Aug 11, 2026 | Khosla RachnaSVP, Business Development | Sold on the market | −2,000 | $412.57 | $825K | Form 4 ↗ |
| Aug 7, 2026 | Busch Matthew C.VP, Finance & CAO | Award | +730 | — | — | Form 4 ↗ |
| Aug 7, 2026 | Ishrak OmarDirector | Award | +85 | — | — | Form 4 ↗ |
| Aug 7, 2026 | Holley Charles MDirector | Award | +103 | — | — | Form 4 ↗ |
| Aug 7, 2026 | Drake Michael VDirector | Award | +64 | — | — | Form 4 ↗ |
| Aug 6, 2026 | Miller DerekSVP, Human Resources | Option exercise | +3,890 | $169.56average | $660K | Form 4 ↗ |
| Aug 6, 2026 | Miller DerekSVP, Human Resources | Sold on the market | −3,890 | $402.54 | $1.6M | Form 4 ↗ |
| Aug 6, 2026 | Grygiel Nancy A.SVP & CCO | Option exercise | +2,970 | $177.41average | $527K | Form 4 ↗ |
| Aug 6, 2026 | Grygiel Nancy A.SVP & CCO | Sold on the market | −2,970 | $402.16 | $1.2M | Form 4 ↗ |
| May 19, 2026 | Miles Amy EDirector | Award | +665 | — | — | Form 4 ↗ |
| May 19, 2026 | Kullman Ellen JamisonDirector | Award | +665 | — | — | Form 4 ↗ |
| May 19, 2026 | Klotman Mary E.Director | Award | +665 | — | — | Form 4 ↗ |
| May 19, 2026 | Jacks TylerDirector | Award | +665 | — | — | Form 4 ↗ |
| May 19, 2026 | Ishrak OmarDirector | Award | +665 | — | — | Form 4 ↗ |
| May 19, 2026 | Holley Charles MDirector | Award | +665 | — | — | Form 4 ↗ |
| May 19, 2026 | Garland Greg C.Director | Award | +665 | — | — | Form 4 ↗ |
| May 19, 2026 | Eckert RobertDirector | Award | +665 | — | — | Form 4 ↗ |
| May 19, 2026 | Druker BrianDirector | Award | +665 | — | — | Form 4 ↗ |
| May 19, 2026 | Drake Michael VDirector | Award | +665 | — | — | Form 4 ↗ |
| May 19, 2026 | Austin Wanda MDirector | Award | +665 | — | — | Form 4 ↗ |
| May 7, 2026 | Busch Matthew C.VP, Finance & CAO | Tax withholding | −41 | $331.11 | $13.6K | Form 4 ↗ |
| May 7, 2026 | Santos EstebanEVP, Operations | Tax withholding | −522 | $331.11 | $173K | Form 4 ↗ |
| May 7, 2026 | Reese David MEVP & CTO | Tax withholding | −556 | $331.11 | $184K | Form 4 ↗ |
| May 7, 2026 | Miller DerekSVP, Human Resources | Tax withholding | −151 | $331.11 | $50K | Form 4 ↗ |
| May 7, 2026 | Khosla RachnaSVP, Business Development | Tax withholding | −93 | $331.11 | $30.8K | Form 4 ↗ |
| May 7, 2026 | Grygiel Nancy A.SVP & CCO | Tax withholding | −88 | $331.11 | $29.1K | Form 4 ↗ |
| May 7, 2026 | Griffith Peter H.EVP & CFO | Tax withholding | −556 | $331.11 | $184K | Form 4 ↗ |
| May 7, 2026 | Graham Jonathan PEVP & Gen. Counsel & Sec. | Tax withholding | −499 | $331.11 | $165K | Form 4 ↗ |
| May 7, 2026 | Gordon MurdoEVP, Global Commercial Ops | Tax withholding | −615 | $331.11 | $204K | Form 4 ↗ |
| May 7, 2026 | Bradway Robert AChairman, CEO and President, Director | Tax withholding | −2,079 | $331.11 | $688K | Form 4 ↗ |
| May 7, 2026 | Bradner James E.EVP, Research and Development | Tax withholding | −446 | $331.11 | $148K | Form 4 ↗ |
| May 6, 2026 | Bradner James E.EVP, Research and Development | Tax withholding | −407 | $329.59 | $134K | Form 4 ↗ |
| May 6, 2026 | Bradway Robert AChairman, CEO and President, Director | Tax withholding | −1,702 | $329.59 | $561K | Form 4 ↗ |
| May 6, 2026 | Busch Matthew C.VP, Finance & CAO | Tax withholding | −50 | $329.59 | $16.5K | Form 4 ↗ |
| May 6, 2026 | Gordon MurdoEVP, Global Commercial Ops | Tax withholding | −502 | $329.59 | $165K | Form 4 ↗ |
| May 6, 2026 | Graham Jonathan PEVP & Gen. Counsel & Sec. | Tax withholding | −408 | $329.59 | $134K | Form 4 ↗ |
| May 6, 2026 | Griffith Peter H.EVP & CFO | Tax withholding | −502 | $329.59 | $165K | Form 4 ↗ |
| May 6, 2026 | Grygiel Nancy A.SVP & CCO | Tax withholding | −76 | $329.59 | $25K | Form 4 ↗ |
| May 6, 2026 | Khosla RachnaSVP, Business Development | Tax withholding | −79 | $329.59 | $26K | Form 4 ↗ |
| May 6, 2026 | Miller DerekSVP, Human Resources | Tax withholding | −123 | $329.59 | $40.5K | Form 4 ↗ |
| May 6, 2026 | Reese David MEVP & CTO | Tax withholding | −454 | $329.59 | $150K | Form 4 ↗ |
| May 6, 2026 | Santos EstebanEVP, Operations | Tax withholding | −427 | $329.59 | $141K | Form 4 ↗ |
| May 5, 2026 | Bradner James E.EVP, Research and Development | Award | +3,337 | — | — | Form 4 ↗ |
| May 5, 2026 | Bradner James E.EVP, Research and Development | AwardNqso (Right to Buy) | +21,773 | $329.59 | $7.2M | Form 4 ↗ |
| May 5, 2026 | Bradway Robert AChairman, CEO and President, Director | Award | +12,136 | — | — | Form 4 ↗ |
| May 5, 2026 | Bradway Robert AChairman, CEO and President, Director | AwardNqso (Right to Buy) | +79,176 | $329.59 | $26.1M | Form 4 ↗ |
| May 5, 2026 | Busch Matthew C.VP, Finance & CAO | Award | +455 | — | — | Form 4 ↗ |
| May 5, 2026 | Busch Matthew C.VP, Finance & CAO | AwardNqso (Right to Buy) | +2,969 | $329.59 | $979K | Form 4 ↗ |
| May 5, 2026 | Gordon MurdoEVP, Global Commercial Ops | Award | +3,640 | — | — | Form 4 ↗ |
| May 5, 2026 | Gordon MurdoEVP, Global Commercial Ops | AwardNqso (Right to Buy) | +23,752 | $329.59 | $7.8M | Form 4 ↗ |
| May 5, 2026 | Graham Jonathan PEVP & Gen. Counsel & Sec. | Award | +2,609 | — | — | Form 4 ↗ |
| May 5, 2026 | Graham Jonathan PEVP & Gen. Counsel & Sec. | AwardNqso (Right to Buy) | +17,022 | $329.59 | $5.6M | Form 4 ↗ |
| May 5, 2026 | Griffith Peter H.EVP & CFO | Award | +3,640 | — | — | Form 4 ↗ |
| May 5, 2026 | Griffith Peter H.EVP & CFO | AwardNqso (Right to Buy) | +23,752 | $329.59 | $7.8M | Form 4 ↗ |
| May 5, 2026 | Grygiel Nancy A.SVP & CCO | Award | +485 | — | — | Form 4 ↗ |
| May 5, 2026 | Grygiel Nancy A.SVP & CCO | AwardNqso (Right to Buy) | +3,167 | $329.59 | $1.0M | Form 4 ↗ |
| May 5, 2026 | Khosla RachnaSVP, Business Development | Award | +500 | — | — | Form 4 ↗ |
| May 5, 2026 | Khosla RachnaSVP, Business Development | AwardNqso (Right to Buy) | +3,266 | $329.59 | $1.1M | Form 4 ↗ |
| May 5, 2026 | Miller DerekSVP, Human Resources | Award | +910 | — | — | Form 4 ↗ |
| May 5, 2026 | Miller DerekSVP, Human Resources | AwardNqso (Right to Buy) | +5,938 | $329.59 | $2.0M | Form 4 ↗ |
| May 5, 2026 | Reese David MEVP & CTO | Award | +2,912 | — | — | Form 4 ↗ |
| May 5, 2026 | Reese David MEVP & CTO | AwardNqso (Right to Buy) | +19,002 | $329.59 | $6.3M | Form 4 ↗ |
| May 5, 2026 | Santos EstebanEVP, Operations | Award | +2,730 | — | — | Form 4 ↗ |
| May 5, 2026 | Santos EstebanEVP, Operations | AwardNqso (Right to Buy) | +17,814 | $329.59 | $5.9M | Form 4 ↗ |
SEC Form 4, public domain. The latest 40 of 86 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR